Target Trial Emulation of 6-Month Weight Change after Endoscopic Sleeve Gastroplasty and Sleeve Gastrectomy: A Retrospective Cohort Study

BACKGROUND: Endoscopic sleeve gastroplasty (ESG) offers a less invasive alternative to sleeve gastrectomy (SG) while preserving gastric anatomy; however, comparative effectiveness data from large real-world cohorts remain limited. Using the 2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) follow-up file, we compared short-term weight-loss and clinical outcomes after ESG and SG. STUDY DESIGN: ESG and SG cases were identified from the 2023 MBSAQIP follow-up file. Using target trial emulation methodology, patients underwent 1:8 nearest-neighbor matching on age, sex, race, diabetes, hypertension, cardiovascular comorbidity, and highest preoperative body mass index. The primary outcome was percent weight change (%WC) from highest preoperative weight to 6 months. The primary analysis used inverse probability of censoring weighting regression to account for missing 6-month weights. Secondary outcomes included 30-day adverse events and 6-month comorbidity and laboratory outcomes. RESULTS: The matched cohort included 3,753 patients (ESG, 417; SG, 3,336). At 6 months, SG achieved greater weight loss than ESG (-18.51% ± 7.98 vs -12.33% ± 6.96; p<0.001). In inverse probability of censoring weighting regression, SG remained associated with greater %WC (ESG coefficient +7.40; 95% CI, 6.59-8.21). Absolute adverse-event rates were low in both groups. SG demonstrated more favorable comorbidity outcomes, whereas ESG was associated with higher 30-day and 6-month readmission (3.8% vs 1.6%) and reoperation (1.0% vs 0.3%) rates. CONCLUSIONS: In this target trial emulation of a national bariatric registry, SG was associated with greater 6-month weight loss and more favorable short-term comorbidity outcomes than ESG. Although ESG produced clinically meaningful weight reduction with low absolute adverse-event rates, its higher readmission and reoperation rates should be considered during procedure selection and patient counseling.

Authors

Institutions

Publication Details

Journal
Journal of the American College of Surgeons
Published
2026-06-17
DOI
https://doi.org/10.1097/xcs.0000000000002072
Primary Topic
Bariatric Surgery and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Target Trial Emulation of 6-Month Weight Change after Endoscopic Sleeve Gastroplasty and Sleeve Gastrectomy: A Retrospective Cohort Study

Sruthi Shankar, D Leslie, Sayeed Ikramuddin, Eric S. Wise et al.
Journal of the American College of Surgeons
Bariatric Surgery and Outcomes
article

Target Trial Emulation of 6-Month Weight Change after Endoscopic Sleeve Gastroplasty and Sleeve Gastrectomy: A Retrospective Cohort Study

Sruthi Shankar, D Leslie, Sayeed Ikramuddin, Eric S. Wise, F. Bazerbachi, Jordan Sauve, Zachary Leslie, Ahmed Dirweesh
article en

Abstract

BACKGROUND: Endoscopic sleeve gastroplasty (ESG) offers a less invasive alternative to sleeve gastrectomy (SG) while preserving gastric anatomy; however, comparative effectiveness data from large real-world cohorts remain limited. Using the 2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) follow-up file, we compared short-term weight-loss and clinical outcomes after ESG and SG. STUDY DESIGN: ESG and SG cases were identified from the 2023 MBSAQIP follow-up file. Using target trial emulation methodology, patients underwent 1:8 nearest-neighbor matching on age, sex, race, diabetes, hypertension, cardiovascular comorbidity, and highest preoperative body mass index. The primary outcome was percent weight change (%WC) from highest preoperative weight to 6 months. The primary analysis used inverse probability of censoring weighting regression to account for missing 6-month weights. Secondary outcomes included 30-day adverse events and 6-month comorbidity and laboratory outcomes. RESULTS: The matched cohort included 3,753 patients (ESG, 417; SG, 3,336). At 6 months, SG achieved greater weight loss than ESG (-18.51% ± 7.98 vs -12.33% ± 6.96; p<0.001). In inverse probability of censoring weighting regression, SG remained associated with greater %WC (ESG coefficient +7.40; 95% CI, 6.59-8.21). Absolute adverse-event rates were low in both groups. SG demonstrated more favorable comorbidity outcomes, whereas ESG was associated with higher 30-day and 6-month readmission (3.8% vs 1.6%) and reoperation (1.0% vs 0.3%) rates. CONCLUSIONS: In this target trial emulation of a national bariatric registry, SG was associated with greater 6-month weight loss and more favorable short-term comorbidity outcomes than ESG. Although ESG produced clinically meaningful weight reduction with low absolute adverse-event rates, its higher readmission and reoperation rates should be considered during procedure selection and patient counseling.

Journal of the American College of Surgeons
University of Minnesota Medical Center (US)
Openalex Percentile: Top 6%
Bariatric Surgery and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.